Conditional survival of malignant thymoma using national population-based Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2011)

Ellen Kim, Charles Thomas

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Thymoma is a rare and unique tumor with a long natural history that makes it difficult to study. Consequently, there is a dearth of prospective diagnostic or therapeutic clinical trials. To our knowledge, there has not been an analysis of conditional survival of thymoma in the literature. The specific aim of this study was to study the 5-year conditional survivals of a large population of thymoma patients. Methods: Cases of thymoma were extracted from the Surveillance, Epidemiology, and End Results registry (1973-2011) and categorized into Masaoka-Koga stage groupings. The primary outcomes compared overall survival (OS), cause specific survival (CSS), and 5-year conditional OS and CSS, by stage. OS and CSS were calculated using the Kaplan-Meier method with the log-rank test for significance using SAS v9.3. Conditional survival was the probability of surviving an additional 5 years at any point in follow-up, and used analysis of variance to test significance. Results: A total of 2182 patients met inclusion criteria and were categorized as Masaoka-Koga stage groupings of I and IIA ("localized," 24%), IIB ("regional," 16%), III and IV ("distant," 50%), and unknown (10%). Median age was 56 (18-91), and 53% were male. Earlier stages had better OS (p <0.0001) and CSS (p <0.0001). Twenty-year OS for local, regional, and distant stages were 42%, 30%, and 18%, respectively. Conditional survivals remained largely unchanged throughout follow-up. Conclusions: Conditional survival provides more relevant survival estimates for patients during follow-up. Further studies should investigate the possibility that thymoma should be considered a chronic disease.

Original languageEnglish (US)
Pages (from-to)701-707
Number of pages7
JournalJournal of Thoracic Oncology
Volume10
Issue number4
DOIs
StatePublished - Apr 30 2015

Fingerprint

Population Surveillance
Thymoma
Registries
Epidemiology
Survival
Survival Analysis
Natural History

Keywords

  • Cancer survivorship
  • Conditional survival
  • SEER
  • Thymoma

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

@article{cd9aa4509c6a4c2caab52124d2eba625,
title = "Conditional survival of malignant thymoma using national population-based Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2011)",
abstract = "Introduction: Thymoma is a rare and unique tumor with a long natural history that makes it difficult to study. Consequently, there is a dearth of prospective diagnostic or therapeutic clinical trials. To our knowledge, there has not been an analysis of conditional survival of thymoma in the literature. The specific aim of this study was to study the 5-year conditional survivals of a large population of thymoma patients. Methods: Cases of thymoma were extracted from the Surveillance, Epidemiology, and End Results registry (1973-2011) and categorized into Masaoka-Koga stage groupings. The primary outcomes compared overall survival (OS), cause specific survival (CSS), and 5-year conditional OS and CSS, by stage. OS and CSS were calculated using the Kaplan-Meier method with the log-rank test for significance using SAS v9.3. Conditional survival was the probability of surviving an additional 5 years at any point in follow-up, and used analysis of variance to test significance. Results: A total of 2182 patients met inclusion criteria and were categorized as Masaoka-Koga stage groupings of I and IIA ({"}localized,{"} 24{\%}), IIB ({"}regional,{"} 16{\%}), III and IV ({"}distant,{"} 50{\%}), and unknown (10{\%}). Median age was 56 (18-91), and 53{\%} were male. Earlier stages had better OS (p <0.0001) and CSS (p <0.0001). Twenty-year OS for local, regional, and distant stages were 42{\%}, 30{\%}, and 18{\%}, respectively. Conditional survivals remained largely unchanged throughout follow-up. Conclusions: Conditional survival provides more relevant survival estimates for patients during follow-up. Further studies should investigate the possibility that thymoma should be considered a chronic disease.",
keywords = "Cancer survivorship, Conditional survival, SEER, Thymoma",
author = "Ellen Kim and Charles Thomas",
year = "2015",
month = "4",
day = "30",
doi = "10.1097/JTO.0000000000000472",
language = "English (US)",
volume = "10",
pages = "701--707",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "4",

}

TY - JOUR

T1 - Conditional survival of malignant thymoma using national population-based Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2011)

AU - Kim, Ellen

AU - Thomas, Charles

PY - 2015/4/30

Y1 - 2015/4/30

N2 - Introduction: Thymoma is a rare and unique tumor with a long natural history that makes it difficult to study. Consequently, there is a dearth of prospective diagnostic or therapeutic clinical trials. To our knowledge, there has not been an analysis of conditional survival of thymoma in the literature. The specific aim of this study was to study the 5-year conditional survivals of a large population of thymoma patients. Methods: Cases of thymoma were extracted from the Surveillance, Epidemiology, and End Results registry (1973-2011) and categorized into Masaoka-Koga stage groupings. The primary outcomes compared overall survival (OS), cause specific survival (CSS), and 5-year conditional OS and CSS, by stage. OS and CSS were calculated using the Kaplan-Meier method with the log-rank test for significance using SAS v9.3. Conditional survival was the probability of surviving an additional 5 years at any point in follow-up, and used analysis of variance to test significance. Results: A total of 2182 patients met inclusion criteria and were categorized as Masaoka-Koga stage groupings of I and IIA ("localized," 24%), IIB ("regional," 16%), III and IV ("distant," 50%), and unknown (10%). Median age was 56 (18-91), and 53% were male. Earlier stages had better OS (p <0.0001) and CSS (p <0.0001). Twenty-year OS for local, regional, and distant stages were 42%, 30%, and 18%, respectively. Conditional survivals remained largely unchanged throughout follow-up. Conclusions: Conditional survival provides more relevant survival estimates for patients during follow-up. Further studies should investigate the possibility that thymoma should be considered a chronic disease.

AB - Introduction: Thymoma is a rare and unique tumor with a long natural history that makes it difficult to study. Consequently, there is a dearth of prospective diagnostic or therapeutic clinical trials. To our knowledge, there has not been an analysis of conditional survival of thymoma in the literature. The specific aim of this study was to study the 5-year conditional survivals of a large population of thymoma patients. Methods: Cases of thymoma were extracted from the Surveillance, Epidemiology, and End Results registry (1973-2011) and categorized into Masaoka-Koga stage groupings. The primary outcomes compared overall survival (OS), cause specific survival (CSS), and 5-year conditional OS and CSS, by stage. OS and CSS were calculated using the Kaplan-Meier method with the log-rank test for significance using SAS v9.3. Conditional survival was the probability of surviving an additional 5 years at any point in follow-up, and used analysis of variance to test significance. Results: A total of 2182 patients met inclusion criteria and were categorized as Masaoka-Koga stage groupings of I and IIA ("localized," 24%), IIB ("regional," 16%), III and IV ("distant," 50%), and unknown (10%). Median age was 56 (18-91), and 53% were male. Earlier stages had better OS (p <0.0001) and CSS (p <0.0001). Twenty-year OS for local, regional, and distant stages were 42%, 30%, and 18%, respectively. Conditional survivals remained largely unchanged throughout follow-up. Conclusions: Conditional survival provides more relevant survival estimates for patients during follow-up. Further studies should investigate the possibility that thymoma should be considered a chronic disease.

KW - Cancer survivorship

KW - Conditional survival

KW - SEER

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=84938292260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938292260&partnerID=8YFLogxK

U2 - 10.1097/JTO.0000000000000472

DO - 10.1097/JTO.0000000000000472

M3 - Article

C2 - 25590603

AN - SCOPUS:84938292260

VL - 10

SP - 701

EP - 707

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 4

ER -